Table 1.
Baseline situation of the study population.
| Variable | Total (n = 1055) | Hypoproteinemia group (n = 924) | Normal group (n = 131) | P |
|---|---|---|---|---|
| Age, median (IQR) | 67.0 (55.0–79.3) | 67.1 (55.8–79.3) | 64.3 (49.9–80.3) | 0.22 |
| Male, n (%) | 600 (56.8) | 520 (56.2) | 80 (61.0) | 0.30 |
| BMI, median (IQR) | 28 (24.1–32.8) | 27.9 (24.0–32.7) | 28.7(24.5–33) | 0.89 |
| SOFA score, median (IQR) | 8 (5–11) | 8 (5–11) | 7 (4–10) | 0.23 |
| SAPSII score, median (IQR) | 47 (36–58) | 48 (37–59) | 43 (31–54) | < 0.01 |
| Sepsis, n (%) | ||||
| Septic shock | 746 (70.7) | 664 (71.8) | 82 (62.5) | 0.03 |
| Severe sepsis | 1053 (99.8) | 922 (99.7) | 131 (100) | 0.59 |
| Comorbidities, n (%) | ||||
| COPD | 22 (2.0) | 18 (1.9) | 4 (3.0) | 0.41 |
| Coronary heart disease | 211 (20) | 182 (19.6) | 29 (22.1) | 0.51 |
| Hypertension | 427 (30.9) | 376 (40.6) | 51 (38.9) | 0.70 |
| Heart failure | 318 (30.1) | 275 (29.7) | 43 (32.8) | 0.48 |
| Cerebrovascular accident | 4 (0.3) | 3 (0.3) | 1 (0.7) | 0.45 |
| Chronic kidney disease | 215 (20.3) | 179 (19.3) | 36 (27.4) | 0.03 |
| Diabetes | 352 (33.3) | 300 (32.4) | 52 (39.6) | 0.10 |
| Laboratory examination on admission, median (IQR) | ||||
| White blood cells (109/L) | 12.9 (7.6–18.5) | 13 (7.6–18.8) | 12.1 (7.6–17.5) | 0.21 |
| Hemoglobin (g/dL) | 10.2 (9–11.8) | 10.2 (9–11.6) | 10.8 (9.2–12.3) | 0.07 |
| Platelets (109/L) | 183 (114–269) | 187 (116–276) | 173 (101–222) | < 0.01 |
| Blood potassium (mmol/L)) | 4 (3.6–4.5) | 4 (3.6–4.5) | 4 (3.6–4.5) | 0.88 |
| Blood sodium (mmol/L) | 138 (134–141) | 138 (134–141) | 138 (135–141) | 0.89 |
| Blood sugar, (mg/dL) | 129 (102–168) | 128 (101–168) | 137 (111–180) | 0.21 |
| Serum albumin (g/dL) | 2.6 (2.2–3) | 2.5 (2.1–2.9) | 3.3 (3.2–3.7) | < 0.01 |
| Blood lactic acid (mmol/L) | 2 (1.3–3.1) | 2 (1.3–3.1) | 1.8 (1.4–3.1) | 0.87 |
| Blood creatinine (mg/dL) | 1.4 (0.9–2.4) | 1.4 (0.9–2.4) | 1.6 (1–3) | 0.03 |
| The lowest in-hospital albumin level (g/dL), median (IQR) | 2.3 (2–2.8) | 2.2 (1.9–2.6) | 3.3 (3.1–3.5) | < 0.01 |
| Albumin supplementatio, n (%) | 350 (33.1%) | 318 (34.4%) | 32 (24.4%) | 0.02 |
| The use of vasoactive drugs, n (%) | 801 (75.9%) | 722 (78.1%) | 79 (60.3%) | < 0.01 |
| The use of mechanical ventilation), n (%) | 632 (59.9%) | 567 (61.3%) | 65 (49.6%) | 0.01 |